AI Summary & Key Takeaways
AI InsightWhen hematologic parameters were eveluated, LHRH agonists significantly decreased hemoglobin levels, median decrease was about 1 gr/dl p
📌 3 Key Takeaways
Abstract
Purpose: In this study, we aimed to analyze metabolic and hematologic long term effects in prostate cancer patients receiving andogen deprivation therapy ADT . Material and Methods: In last 3 years 50 patients with metastatic prostate cancer treated with LHRH agonists in our department were retrospectively evaluated. The median age was 74.8 years. Serum levels of glucose, total cholesterol, lipoproteins LDL, HDL and hemogram parameters, that measured at baseline and first, second and third years after treatment, were compared. The statistical analysis in this study was performed with SPSS for Windows Version 15.0 Inc., Chicago, IL . p0,05 . Serum total cholesterol TC , triglyceride TG , low-density lipoprotein LDL levels increased significantly, p0,05 . When hematologic parameters were eveluated, LHRH agonists significantly decreased hemoglobin levels, median decrease was about 1 gr/dl p
Özet
Amaç: Bu çalışmada amacımız androjen deprivasyon tedavisi ADT alan prostat kanserli hastalardaki hematolojik ve metabolik uzun dönem etkileri analiz etmektir. Gereç ve Yöntemler: Kliniğimizde son 3 yılda metastatik prostat kanseri tanısıyla LHRH agonisti ile androjen deprivasyon tedavisi alan 50 hasta retrospektif olarak değerlendirildi. Hastaların ortalama yaşı 74.8 yıldı. Hastaların tedavi başlangıcındaki ve sonraki 1., 2., ve 3. yıl serum glukoz , total kolesterol , trigliserid , serum lipoproteinleri LDL, HDL ve tam kan sayımı parametreleri karşılaştırıldı. Bu çalışmada istatistiksel analiz SPSS for Windows Version 15.0 paket programıyla yapıldı. p0.05 . Serum total kolesterol, trigliserid ve low-densiy lipoprotein LDL seviyelerinde istatistiksel olarak anlamlı artış izlendi, sırasıyla p